Table 2 Association between CIP2A expression in patients with acute myeloid leukemia and demographic characteristics, clinical and laboratory data, and risk stratification
From: Prognostic value of CIP2A gene expression in adult Egyptian acute myeloid leukemia patients
Parameter | CIP2A expression | P value | |
|---|---|---|---|
| Â | High (n = 21) | Low (n = 39) | Â |
|  | Value (mean ± SD) or distribution (n (%)) | Value (mean ± SD) or distribution (n (%)) |  |
Age (years) | 33.8 ± 2.7 | 38.5 ± 2.0 | 0.17 |
Gender | 0.83 | ||
 Male | 9 (33.3) | 18 (66.7) |  |
 Female | 12 (36.3) | 21 (63.7) |  |
Hepatomegaly | 7 (28.0) | 18 (72.0) | 0.28 |
Splenomegaly | 5 (21.7) | 18 (78.2) | 0.11 |
Lymphadenopathy | 1 (8.3) | 11 (91.6) | 0.04 |
Total leukocyte count (× 109/L) | 41.6 ± 10.6 | 54.3 ± 10.2 | 0.43 |
Hemoglobin (g/dL) | 8.2 ± 0.4 | 8.0 ± 0.3 | 0.81 |
Platelets (× 109/L) | 45.5 ± 9.6 | 62.8 ± 14.3 | 0.41 |
Peripheral-blood blasts | 45.8 ± 5.6 | 47.9 ± 4.5 | 0.78 |
Bone-marrow blasts | 58.7 ± 4.3 | 61.7 ± 3.6 | 0.61 |
FLT3 | 0.38 | ||
 Wild type | 19 (90.5) | 32 (82.1) |  |
 Mutant | 2 (9.5) | 7 (17.9) |  |
Risk stratification | 0.94 | ||
 Favorable | 5 (23.8) | 9 (23.1) |  |
 Intermediate | 3 (14.3) | 8 (20.5) |  |
 Poor | 5 (23.8) | 9 (23.1) |  |
 Not performed | 8 (38.1) | 13 (33.3) |  |